

**Table S5: Datasets for biomarker meta-analysis**

Reference	GEO Accession Number	Availability	Sample Number	Platform Type
<b>Bild et al., 2006 (Bild et al., 2006)</b>	GSE3143	Raw CEL files	158	<b>Affymetrix Human Genome U95 Version 2 Array</b>
<b>Calabro et al., 2009 (Calabro et al., 2009)</b>	GSE10510	Raw data available	152	<b>DKFZ Division of Molecular Genome Analysis Human Operon 4.0 oligo Array 35k</b>
<b>Chang et al., 2005 (Chang et al., 2005)</b>	NA	Processed only	295	<b>Agilent 21K oligo array</b>
<b>Chanrion et al., 2008 (Chanrion et al., 2008)</b>	GSE9893	Raw data available	155	<b>MLRG Human 21K V12.0</b>
<b>Desmedt et al., 2007 (Desmedt et al., 2007)</b>	GSE7390	Raw CEL files	198	<b>Affymetrix U133A</b>
<b>Hu et al., 2006 (Hu et al., 2006)</b>	GSE1992	Processed only	99	<b>Agilent 21K oligo array</b>
<b>Miller et al., 2005 (Miller et al., 2005)</b>	GSE3494	Raw CEL files	251	<b>Affymetrix U133A/B</b>
<b>Pawitan et al., 2005 (Pawitan et al., 2005)</b>	GSE1456	Raw CEL files	159	<b>Affymetrix U133A/B</b>
<b>Total</b>			<b>1467</b>	

**References**

Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M. B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature* 439, 353-357.

Calabro, A., Beissbarth, T., Kuner, R., Stojanov, M., Benner, A., Asslaber, M., Ploner, F., Zatloukal, K., Samonigg, H., Poustka, A., and Sultmann, H. (2009). Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. *Breast Cancer Res Treat* 116, 69-77.

Chang, H. Y., Nuyten, D. S., Sneddon, J. B., Hastie, T., Tibshirani, R., Sorlie, T., Dai, H., He, Y. D., van't Veer, L. J., Bartelink, H., et al. (2005). Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. *Proc Natl Acad Sci U S A* 102, 3738-3743.

Chanrion, M., Negre, V., Fontaine, H., Salvetat, N., Bibeau, F., Mac Grogan, G., Mauriac, L., Katsaros, D., Molina, F., Theillet, C., and Darbon, J. M. (2008). A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. *Clin Cancer Res* 14, 1744-1752.

Desmedt, C., Piette, F., Loi, S., Wang, Y., Lallemand, F., Haibe-Kains, B., Viale, G., Delorenzi, M., Zhang, Y., d'Assignies, M. S., et al. (2007). Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. *Clin Cancer Res* 13, 3207-3214.

Hu, Z., Fan, C., Oh, D. S., Marron, J. S., He, X., Qaqish, B. F., Livasy, C., Carey, L. A., Reynolds, E., Dressler, L., et al. (2006). The molecular portraits of breast tumors are conserved across microarray platforms. *BMC Genomics* 7, 96.

Miller, L. D., Smeds, J., George, J., Vega, V. B., Vergara, L., Ploner, A., Pawitan, Y., Hall, P., Klaar, S., Liu, E. T., and Bergh, J. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. *Proc Natl Acad Sci U S A* 102, 13550-13555.

Pawitan, Y., Bjohle, J., Amler, L., Borg, A. L., Egyhazi, S., Hall, P., Han, X., Holmberg, L., Huang, F., Klaar, S., et al. (2005). Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. *Breast Cancer Res* 7, R953-964.